Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.

Innocenti I, Morelli F, Autore F, Tomasso A, Corbingi A, Bellesi S, Za T, De Stefano V, Laurenti L.

Leuk Lymphoma. 2019 May 20:1-3. doi: 10.1080/10428194.2019.1612063. [Epub ahead of print] No abstract available.

PMID:
31106622
2.

HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia.

Pagotto S, Veronese A, Soranno A, Balatti V, Ramassone A, Guanciali-Franchi PE, Palka G, Innocenti I, Autore F, Rassenti LZ, Kipps TJ, Mariani-Costantini R, Laurenti L, Croce CM, Visone R.

Cancers (Basel). 2019 Apr 23;11(4). pii: E575. doi: 10.3390/cancers11040575.

3.

Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience.

Autore F, Innocenti I, Morelli F, Sorà F, Corbingi A, Fianchi L, Criscuolo M, Pagano L, Sica S, Laurenti L.

Hematol Oncol. 2019 Apr 24. doi: 10.1002/hon.2623. [Epub ahead of print] No abstract available.

PMID:
31017684
4.

Ibrutinib-associated palmo-plantar fissures in a patient with Chronic Lymphocytic Leukaemia: a novel cutaneous adverse event.

Sollena P, Mannino M, Laurenti L, De Simone C, Peris K.

J Eur Acad Dermatol Venereol. 2019 Apr 16. doi: 10.1111/jdv.15632. [Epub ahead of print] No abstract available.

PMID:
30989712
5.

Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol.

La Rocca U, Perrone MP, Piciocchi A, Cinti P, Barberi W, Gozzer M, Baftii MS, Torelli GF, Quattrocchi L, Gesuiti P, Lattanzi R, Cavallari C, Ricci R, Laurenti L, Foà R, Girelli G, Iori AP.

Bone Marrow Transplant. 2019 Mar 4. doi: 10.1038/s41409-019-0497-1. [Epub ahead of print] No abstract available.

PMID:
30833741
6.

HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.

Innocenti I, Morelli F, Autore F, Corbingi A, Pasquale R, Sorà F, Pompili M, Laurenti L.

Leuk Lymphoma. 2019 May;60(5):1340-1342. doi: 10.1080/10428194.2018.1523401. Epub 2019 Feb 7. No abstract available.

PMID:
30730231
7.

Unrelated cord blood transplantation and post-transplant cyclophosphamide.

Bacigalupo A, Sica S, Laurenti L, Sora' F, Giammarco S, Metafuni E, Innocenti I, Autore F, Teofili L, Bianchi M, Chiusolo P.

Haematologica. 2019 Feb;104(2):e77-e78. doi: 10.3324/haematol.2018.202598. Epub 2018 Dec 20. No abstract available.

8.

Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid.

Autore F, Chiusolo P, Sorà F, Giammarco S, Laurenti L, Innocenti I, Metafuni E, Piccirillo N, Pagano L, Bacigalupo A, Leone G, Sica S.

Leuk Lymphoma. 2019 May;60(5):1328-1330. doi: 10.1080/10428194.2018.1522436. Epub 2018 Dec 11. No abstract available.

PMID:
30526180
9.

External validation of the accuracy of 'CLLflow score'.

D'Arena G, Vitale C, Coscia M, D'Auria F, Bellesi S, Topini G, Panichi V, Valvano L, Statuto T, Corrente F, Laurenti L.

J Investig Med. 2018 Oct;66(7):e6. doi: 10.1136/jim-2018-000832. Epub 2018 Sep 14. No abstract available.

PMID:
30217834
10.

Peripheral Nervous System Involvement in Lymphoproliferative Disorders.

Sabatelli M, Laurenti L, Luigetti M.

Mediterr J Hematol Infect Dis. 2018 Sep 1;10(1):e2018057. doi: 10.4084/MJHID.2018.057. eCollection 2018. Review.

11.

Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.

Tedeschi A, Conticello C, Rizzi R, Benevolo G, Laurenti L, Petrucci MT, Zaja F, Varettoni M.

Hematol Oncol. 2019 Apr;37(2):117-128. doi: 10.1002/hon.2539. Epub 2018 Sep 7. Review.

PMID:
30192023
12.

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment.

Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, Del Principe MI, Cutrona G, Angeletti I, Coscia M, Herishanu Y, Chiarenza A, Molica S, Ciolli S, Goldschmidt N, Angrilli F, Giordano A, Rago A, Bairey O, Tripepi G, Chaffee KG, Sameer PA, Vigna E, Zirlik K, Shvidel L, Innocenti I, Recchia AG, Di Raimondo F, Del Poeta G, Cortelezzi A, Neri A, Ferrarini M, Gaidano G, Kay NE, Polliack A, Foà R, Morabito F.

Eur J Haematol. 2018 Jul 24. doi: 10.1111/ejh.13149. [Epub ahead of print] No abstract available.

PMID:
30039576
13.

Molecular Filters for Noise Reduction.

Laurenti L, Csikasz-Nagy A, Kwiatkowska M, Cardelli L.

Biophys J. 2018 Jun 19;114(12):3000-3011. doi: 10.1016/j.bpj.2018.05.009.

14.

Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2.

Bittremieux M, La Rovere RM, Akl H, Martines C, Welkenhuyzen K, Dubron K, Baes M, Janssens A, Vandenberghe P, Laurenti L, Rietdorf K, Morciano G, Pinton P, Mikoshiba K, Bootman MD, Efremov DG, De Smedt H, Parys JB, Bultynck G.

Cell Death Differ. 2019 Mar;26(3):531-547. doi: 10.1038/s41418-018-0142-3. Epub 2018 Jun 13.

15.

Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants.

Metafuni E, Chiusolo P, Sica S, Laurenti L, Bregante S, Van Lint MT, Dominietto A, Angelucci E, Bacigalupo A.

Bone Marrow Transplant. 2018 Dec;53(12):1560-1567. doi: 10.1038/s41409-018-0200-y. Epub 2018 May 24.

16.

Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review.

Autore F, Strati P, Laurenti L, Ferrajoli A.

Haematologica. 2018 Jun;103(6):931-938. doi: 10.3324/haematol.2017.186684. Epub 2018 May 10. Review.

17.

High vs low dose cyclosporine-a, after allogeneic marrow transplantation in leukemia: Long term follow up of a randomized study.

Bacigalupo A, Van Lint MT, Sica S, Laurenti L, Rosales MB, Dominietto A, di Grazia C, Angelucci E.

Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25131. [Epub ahead of print] No abstract available.

18.

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Perez AM, Coscia M, Laurenti L, Musuraca G, Farina L, Delgado AR, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P; GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum.

Haematologica. 2018 Jul;103(7):1209-1217. doi: 10.3324/haematol.2018.189837. Epub 2018 Apr 19.

19.

CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia.

D'Arena G, Vitale C, Rossi G, Coscia M, Omedè P, D'Auria F, Statuto T, Valvano L, Ciolli S, Gilestro M, Molica S, Bellesi S, Topini G, Panichi V, Autore F, Innocenti I, Musto P, Deaglio S, Laurenti L, Del Vecchio L.

Hematol Oncol. 2018 Mar 30. doi: 10.1002/hon.2510. [Epub ahead of print]

PMID:
29602219
20.

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.

Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe MI, Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A, Giordano A, Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G, Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foà R, Polliack A, Morabito F.

Leukemia. 2018 Aug;32(8):1869-1873. doi: 10.1038/s41375-018-0100-6. Epub 2018 Mar 20. No abstract available.

PMID:
29588545
21.

Programming discrete distributions with chemical reaction networks.

Cardelli L, Kwiatkowska M, Laurenti L.

Nat Comput. 2018;17(1):131-145. doi: 10.1007/s11047-017-9667-5. Epub 2017 Dec 8.

22.

Identifying the Best Haploidentical Donor: Are We There?

Bacigalupo A, Laurenti L.

Biol Blood Marrow Transplant. 2018 Apr;24(4):638-640. doi: 10.1016/j.bbmt.2018.03.003. Epub 2018 Mar 12. No abstract available.

23.

Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia.

Innocenti I, Rossi D, Trapè G, Autore F, Larocca LM, Gomes V, Cerri M, Falcucci P, Sica S, Gaidano G, Laurenti L.

Hematol Oncol. 2018 Feb 27. doi: 10.1002/hon.2502. [Epub ahead of print]

PMID:
29484684
24.

Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies.

D'Arena G, Vitale C, Coscia M, Festa A, Di Minno NMD, De Feo V, Caraglia M, Calapai G, Laurenti L, Musto P, Di Minno G, Fenoglio D.

J Immunol Res. 2017;2017:1832968. doi: 10.1155/2017/1832968. Epub 2017 Dec 21. Review.

25.

Allogeneic Hematopoietic Stem Cell Transplantation In Therapy-Related Myeloid Neoplasms (t-MN) of the Adult: Monocentric Observational Study and Review of the Literature.

Metafuni E, Chiusolo P, Laurenti L, Sorà F, Giammarco S, Bacigalupo A, Leone G, Sica S.

Mediterr J Hematol Infect Dis. 2018 Jan 1;10(1):e2018005. doi: 10.4084/MJHID.2018.005. eCollection 2018.

26.

Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients.

Alberelli MA, Innocenti I, Autore F, Laurenti L, De Candia E.

Haematologica. 2018 Mar;103(3):e119-e122. doi: 10.3324/haematol.2017.179044. Epub 2017 Dec 14. No abstract available.

27.

Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy.

Aiello A, D'Ausilio A, Lo Muto R, Randon F, Laurenti L.

J Mark Access Health Policy. 2017 Nov 7;5(1):1393308. doi: 10.1080/20016689.2017.1393308. eCollection 2017.

28.

Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.

Gentile M, Shanafelt TD, Mauro FR, Laurenti L, Rossi D, Molica S, Vincelli I, Cutrona G, Uccello G, Pepe S, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F.

Am J Hematol. 2018 Feb;93(2):E35-E37. doi: 10.1002/ajh.24960. Epub 2017 Nov 23. No abstract available.

29.

Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.

Innocenti I, Autore F, Pasquale R, Morelli F, Efremov DG, Laurenti L.

Expert Rev Hematol. 2017 Dec;10(12):1069-1076. doi: 10.1080/17474086.2017.1398642. Epub 2017 Nov 3. Review.

PMID:
29082795
30.

Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome.

Autore F, Innocenti I, Luigetti M, Piccirillo N, Sora F, Chiusolo P, Sica S, Bacigalupo A, Laurenti L.

Hematol Oncol. 2018 Apr;36(2):392-398. doi: 10.1002/hon.2478. Epub 2017 Sep 15. Review.

PMID:
28913957
31.

HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.

Bobrowicz M, Dwojak M, Pyrzynska B, Stachura J, Muchowicz A, Berthel E, Dalla-Venezia N, Kozikowski M, Siernicka M, Miazek N, Zapala P, Domagala A, Bojarczuk K, Malenda A, Barankiewicz J, Graczyk-Jarzynka A, Zagozdzon A, Gabrysiak M, Diaz JJ, Karp M, Lech-Maranda E, Firczuk M, Giannopoulos K, Efremov DG, Laurenti L, Baatout D, Frenzel L, Malinowska A, Slabicki M, Zenz T, Zerrouqi A, Golab J, Winiarska M.

Blood. 2017 Oct 5;130(14):1628-1638. doi: 10.1182/blood-2016-08-736066. Epub 2017 Aug 22.

32.

Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia.

D'Arena G, Vitale C, Perbellini O, Coscia M, La Rocca F, Ruggieri V, Visco C, Di Minno NMD, Innocenti I, Pizza V, Deaglio S, Di Minno G, Giudice A, Calapai G, Musto P, Laurenti L, Iorio EL.

Eur J Haematol. 2017 Oct;99(4):306-314. doi: 10.1111/ejh.12918. Epub 2017 Aug 3.

PMID:
28646624
33.

Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.

Maffei R, Fiorcari S, Martinelli S, Benatti S, Bulgarelli J, Rizzotto L, Debbia G, Santachiara R, Rigolin GM, Forconi F, Rossi D, Laurenti L, Palumbo GA, Vallisa D, Cuneo A, Gaidano G, Luppi M, Marasca R.

Leuk Lymphoma. 2018 Feb;59(2):423-433. doi: 10.1080/10428194.2017.1339872. Epub 2017 Jun 22.

PMID:
28639485
34.

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.

Laurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G, D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B, Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D, Liberati AM, Russo F, Foá R.

Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8. No abstract available.

35.

Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.

D'Arena G, Simeon V, Laurenti L, Cimminiello M, Innocenti I, Gilio M, Padula A, Vigliotti ML, De Lorenzo S, Loseto G, Passarelli A, Di Minno MND, Tucci M, De Feo V, D'Auria F, Silvestris F, Di Minno G, Musto P.

Leuk Lymphoma. 2017 Nov;58(11):2633-2641. doi: 10.1080/10428194.2017.1306648. Epub 2017 Apr 3.

PMID:
28367662
36.

Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.

Mauro FR, Galieni P, Tedeschi A, Laurenti L, Del Poeta G, Reda G, Motta M, Gozzetti A, Murru R, Caputo MD, Campanelli M, Frustaci AM, Innocenti I, Raponi S, Guarini A, Morabito F, Foà R, Gentile M.

Am J Hematol. 2017 Jun;92(6):529-535. doi: 10.1002/ajh.24714. Epub 2017 Apr 18.

37.

H1N1 Influenza among Hematological Patients: Monocentric Influenza Cases from 2011 to 2016.

Metafuni E, Santangelo R, Chiusolo P, Laurenti L, Sorà F, Giammarco S, Sica S.

Mediterr J Hematol Infect Dis. 2017 Mar 1;9(1):e2017024. doi: 10.4084/MJHID.2017.024. eCollection 2017. No abstract available.

38.

Hyperleukocytosis and leukostasis: management of a medical emergency.

Giammarco S, Chiusolo P, Piccirillo N, Di Giovanni A, Metafuni E, Laurenti L, Sica S, Pagano L.

Expert Rev Hematol. 2017 Feb;10(2):147-154. doi: 10.1080/17474086.2017.1270754. Epub 2016 Dec 26. Review.

PMID:
27967252
39.

Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study.

Tisi MC, Hohaus S, Cuccaro A, Innocenti I, De Carolis E, Za T, D'Alò F, Laurenti L, Fianchi L, Sica S, Sanguinetti M, De Stefano V, Pagano L.

Haematologica. 2017 Mar;102(3):e108-e111. doi: 10.3324/haematol.2016.151837. Epub 2016 Nov 17. No abstract available.

40.

Stochastic analysis of Chemical Reaction Networks using Linear Noise Approximation.

Cardelli L, Kwiatkowska M, Laurenti L.

Biosystems. 2016 Nov;149:26-33. doi: 10.1016/j.biosystems.2016.09.004. Epub 2016 Oct 29.

41.

MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report.

Caivano A, La Rocca F, Simeon V, Girasole M, Dinarelli S, Laurenzana I, De Stradis A, De Luca L, Trino S, Traficante A, D'Arena G, Mansueto G, Villani O, Pietrantuono G, Laurenti L, Del Vecchio L, Musto P.

Cell Oncol (Dordr). 2017 Feb;40(1):97-103. doi: 10.1007/s13402-016-0300-x. Epub 2016 Oct 19.

PMID:
27761889
42.

Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia.

De Luca L, D'Arena G, Simeon V, Trino S, Laurenzana I, Caivano A, La Rocca F, Villani O, Mansueto G, Deaglio S, Innocenti I, Laurenti L, Molica S, Pietrantuono G, De Stradis A, Del Vecchio L, Musto P.

Leuk Lymphoma. 2017 Jun;58(6):1424-1432. doi: 10.1080/10428194.2016.1243790. Epub 2016 Oct 14.

PMID:
27739922
43.

Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.

Gentile M, Shanafelt TD, Rossi D, Laurenti L, Mauro FR, Molica S, Cutrona G, Uccello G, Campanelli M, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F.

Blood. 2016 Oct 20;128(16):2093-2095. doi: 10.1182/blood-2016-07-728261. Epub 2016 Aug 22. No abstract available.

44.

Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Sorà F, Ponziani FR, Laurenti L, Chiusolo P, Autore F, Gasbarrini A, Sica S, Pompili M.

Leuk Lymphoma. 2017 Apr;58(4):993-995. doi: 10.1080/10428194.2016.1219906. Epub 2016 Aug 22. No abstract available.

PMID:
27546591
45.

Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role.

D'Arena G, Rossi G, Laurenti L, Statuto T, D'Auria F, Valvano L, Simeon V, Giudice A, Innocenti I, De Feo V, Filosa R, Musto P.

J Immunol Res. 2016;2016:9271469. doi: 10.1155/2016/9271469. Epub 2016 Jul 14.

46.

Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia.

Sorà F, Chiusolo P, Laurenti L, Autore F, Giammarco S, Sica S.

Mediterr J Hematol Infect Dis. 2016 Jul 1;8(1):e2016027. doi: 10.4084/MJHID.2016.027. eCollection 2016.

47.

PO-54 - Clinical and laboratory characterization of platelet dysfunction caused by ibrutinib treatment in patients with chronic lymphocytic leukemia.

Alberelli MA, Innocenti I, Sica S, Laurenti L, De Candia E.

Thromb Res. 2016 Apr;140 Suppl 1:S196. doi: 10.1016/S0049-3848(16)30187-6. Epub 2016 Apr 8.

PMID:
27161742
48.

BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.

Bojarczuk K, Sasi BK, Gobessi S, Innocenti I, Pozzato G, Laurenti L, Efremov DG.

Blood. 2016 Jun 23;127(25):3192-201. doi: 10.1182/blood-2015-10-675009. Epub 2016 Apr 19.

49.

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab.

Laurenti L, Innocenti I, Autore F, Sica S, Efremov DG.

Onco Targets Ther. 2016 Jan 20;9:421-9. doi: 10.2147/OTT.S72845. eCollection 2016. Review.

50.

Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience.

Laurenti L, Autore F, Innocenti I, D'Arena G, Coscia M, Mondello P, Chiusolo P, Bellesi S, Efremov DG, Sica S, Mauro FR.

Leuk Lymphoma. 2016 Oct;57(10):2429-31. doi: 10.3109/10428194.2015.1137293. Epub 2016 Jan 27. No abstract available.

PMID:
26818825

Supplemental Content

Loading ...
Support Center